IPO Year: 2025
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2025 | $5.00 | Speculative Buy | The Benchmark Company |
| 7/28/2025 | $6.00 | Buy | Roth Capital |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - CapsoVision, Inc (0001378325) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
The Benchmark Company initiated coverage of CapsoVision with a rating of Speculative Buy and set a new price target of $5.00
Roth Capital initiated coverage of CapsoVision with a rating of Buy and set a new price target of $6.00
Fastest customizable press release news feed in the world
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA. Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 23, 2026, at 10:30–10:55 am PT The fireside chat will
SARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa
SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on Thursday, December 4, 2025 in New York City. If you are interested in arranging a one-on-one meeting with CapsoVision's management team at the conference, please contact your Benchmark representative or reach out to the company
SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its third quarter ended September 30, 2025. Recent Highlights Third quarter 2025 revenue was $3.5 million, a 19% increase over the third quarter of 2024.New accounts grew 31% in the third quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used by over 151,000 patients as of September 30, 2025.Submitted an application to the FDA requesting Breakthrough Device Designation to accelerate development of the Company's endoscopy capsule for use
SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company's CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision's mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseas
SARATOGA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership experience spanning corporate finance, capital markets, and strategic transactions. He joins CapsoVision after serving as Vice President of Financial Planning and Analysis at Matterport, Inc., where he helped lead its initial public offering and played a key role in the company's recent acquisition. His background also i
SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conferen
SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, and Doug Atkinson, Head of Global Sales, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place on Thursday, October 9, 2025, in New York, NY. If you are interested in arranging a one-on-one meeting with CapsoVision's management team at the conference, please contact your ROTH representative or reach out to the company directly at [email protected]. About CapsoVision CapsoV
SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second quarter ended June 30, 2025. Recent Highlights Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024.New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used by over 143,000 patients as of June 30, 2025.Submitted a 510(k) notification to the FDA for CapsoCam Colon®, a non-invasive capsule for colon imaging, in June 2025.Closed initial public offering on
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the c
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4/A - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
3 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
8-K - CapsoVision, Inc (0001378325) (Filer)
10-Q - CapsoVision, Inc (0001378325) (Filer)
8-K - CapsoVision, Inc (0001378325) (Filer)
8-K - CapsoVision, Inc (0001378325) (Filer)
8-K - CapsoVision, Inc (0001378325) (Filer)
SCHEDULE 13G - CapsoVision, Inc (0001378325) (Subject)
8-K - CapsoVision, Inc (0001378325) (Filer)
8-K - CapsoVision, Inc (0001378325) (Filer)
10-Q - CapsoVision, Inc (0001378325) (Filer)
8-K - CapsoVision, Inc (0001378325) (Filer)
Live finance-specific insights
SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conferen
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the c